11(top 5%)
papers
573(top 2%)
citations
11(top 2%)
h-index
11(top 5%)
g-index
11
all documents
593
doc citations
258
citing journals

Top Articles

#TitleJournalYearCitations
1Pain outcomes in patients with advanced breast cancer and bone metastasesCancer2013126
2Hospitalization risks related to vascular access type among incident US hemodialysis patientsNephrology Dialysis Transplantation201194
3Conversion of Vascular Access Type Among Incident Hemodialysis Patients: Description and Association With MortalityAmerican Journal of Kidney Diseases200990
4OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.Journal of Clinical Oncology201367
5Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patientsNephrology Dialysis Transplantation200849
6Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.Journal of Clinical Oncology201443
7Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).Journal of Clinical Oncology201830
8Evolving Statistical Methods to Facilitate Evaluation of the Causal Association Between Erythropoiesis-Stimulating Agent Dose and Mortality in Nonexperimental Research: Strengths and LimitationsAmerican Journal of Kidney Diseases200927
9Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.Journal of Clinical Oncology201426
10OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.Journal of Clinical Oncology201321
11Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).Journal of Clinical Oncology201820